Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Governor Rell Bans House Bill 5021
The bill also prohibited copayments for colonoscopies and required group health insurance policies to offer a health wellness program that provides incentives to participate. The Governor noted that
The bill also prohibited copayments for colonoscopies and required group health insurance policies to offer a health wellness program that provides incentives to participate. The Governor noted that
Repros Therapeutics has an end of phase II meeting scheduled with FDA in September, to discuss a phase III program investigating the use of Proellex in the treatment
FDA has granted marketing approval for AMAG’s Feraheme (ferumoxytol) Injection. It is for intravenous (IV) use as an iron replacement therapy, for the treatment of iron deficiency anemia
Pharmaceutical firm Teva has received FDA approval for the Abbreviated New Drug Application (ANDA) to market Tri-Lo Sprintec, a generic version of Ortho McNeil Janssen’s oral contraceptive, Ortho
The European Commission has granted marketing authorisation for AstraZeneca’s oral anti-cancer drug, IRESSA. It is used for the treatment of adults with locally advanced or metastatic non-small cell
Roche has launched a new program to ease Tamiflu access to developing economies. The Tamiflu Reserves Program is designed as a pandemic insurance policy for the world’s developing
Huhhot Xinheng Baide, a subsidary of Bio-Bridge Science, has acquired a raw bovine serum collection center in Beian City, China, by purchasing serum production equipment at the facility.
Provectus has completed patient enrollment for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is a topical drug for the treatment of dermatologic diseases, including atopic
Graceway and Pfizer have entered into an acquisition and license agreement. Under the deal, Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer,
Morphotek has signed a research collaboration agreement with Synageva to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.